https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1999-01-01 / Urol Int 1999;63(3):151-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1999-01-01 / Urol Int 1999;63(3):151-91999-01-01 00:00:001999-01-01 00:00:00Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1999-01-01 / Cancer Chemother. Pharmacol. 1999;43(5):409-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1999-01-01 / Cancer Chemother. Pharmacol. 1999;43(5):409-141999-01-01 00:00:002019-02-15 09:17:59A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees C whole-body hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1999-01-01 / Gene Ther. 1999 Jan;6(1):63-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1999-01-01 / Gene Ther. 1999 Jan;6(1):63-731999-01-01 00:00:002020-06-23 09:46:30Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1999-01-01 / Infect Dis Obstet Gynecol 1999;7(1-2):91-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1999-01-01 / Infect Dis Obstet Gynecol 1999;7(1-2):91-71999-01-01 00:00:001999-01-01 00:00:00Characterization of mild whole-body hyperthermia protocols using human breast, ovarian, and colon tumors grown in severe combined immunodeficient mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1998-12-01 / Int. J. Oncol. 1998 Dec;13(6):1105-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1998-12-01 / Int. J. Oncol. 1998 Dec;13(6):1105-151998-12-01 00:00:002020-06-23 09:46:52Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1998-12-01 / Mol. Med. 1998 Dec;4(12):783-94
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1998-12-01 / Mol. Med. 1998 Dec;4(12):783-941998-12-01 00:00:001998-12-01 00:00:00A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1998-11-01 / J. Immunol. 1998 Nov;161(9):4520-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1998-11-01 / J. Immunol. 1998 Nov;161(9):4520-91998-11-01 00:00:002019-02-15 08:37:59Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1998-09-01 / Vestn Rentgenol Radiol 1998 Sep-Oct;(5):30-3
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1998-09-01 / Vestn Rentgenol Radiol 1998 Sep-Oct;(5):30-31998-09-01 00:00:002019-02-15 10:00:41[Current methods of radiation therapy in patients with prostatic cancer: subtotal body radiation, local hyperthermia]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1998-06-01 / J Surg Oncol 1998 Jun;68(2):79-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1998-06-01 / J Surg Oncol 1998 Jun;68(2):79-911998-06-01 00:00:002019-02-15 08:53:20Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1998-04-01 / Nat. Biotechnol. 1998 Apr;16(4):364-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1998-04-01 / Nat. Biotechnol. 1998 Apr;16(4):364-91998-04-01 00:00:002019-02-15 08:39:04Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
